See more : International Paper Company PFD $4 (INPAP) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Pharmaceuticals Inc. (MIST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kyoto Group AS (KYOTO.OL) Income Statement Analysis – Financial Results
- ZIM Corporation (ZIMCF) Income Statement Analysis – Financial Results
- Sky ICT Public Company Limited (SKY.BK) Income Statement Analysis – Financial Results
- Sagarsoft (India) Limited (SAGARSOFT.BO) Income Statement Analysis – Financial Results
- Fukushima Galilei Co.Ltd. (FKSHF) Income Statement Analysis – Financial Results
Milestone Pharmaceuticals Inc. (MIST)
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 480.00K | 0.00 | 376.00K | 236.00K | 10.00K | 8.00K |
| Gross Profit | 1.00M | 4.52M | 15.00M | -376.00K | -236.00K | -10.00K | -8.00K |
| Gross Profit Ratio | 100.00% | 90.40% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.05M | 39.83M | 38.67M | 34.49M | 41.99M | 16.85M | 5.64M |
| General & Administrative | 15.93M | 15.72M | 12.40M | 10.29M | 7.00M | 3.05M | 1.50M |
| Selling & Marketing | 15.11M | 9.10M | 7.00M | 5.94M | 8.89M | 3.92M | 1.13M |
| SG&A | 31.05M | 24.81M | 19.40M | 16.22M | 15.90M | 6.97M | 2.63M |
| Other Expenses | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Cost & Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Interest Income | 3.97M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Interest Expense | 2.55M | 0.00 | 0.00 | 726.00K | 2.60M | 0.00 | 0.00 |
| Depreciation & Amortization | 92.00K | 480.00K | 362.00K | 376.00K | 236.00K | 10.00K | 8.00K |
| EBITDA | -56.85M | -58.36M | -42.98M | -50.71M | -57.88M | -23.36M | -8.26M |
| EBITDA Ratio | -5,684.50% | -1,192.84% | -286.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.10M | -59.64M | -43.07M | -50.71M | -57.88M | -23.82M | -8.27M |
| Operating Income Ratio | -6,109.80% | -1,192.84% | -287.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.41M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Income Before Tax | -59.69M | -58.39M | -42.85M | -49.98M | -55.29M | -23.11M | -8.08M |
| Income Before Tax Ratio | -5,968.50% | -1,167.76% | -285.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.25M | -220.00K | -17.00K | -56.00K | 74.00K | 4.00K |
| Net Income | -59.69M | -57.13M | -42.63M | -49.97M | -55.23M | -23.19M | -8.09M |
| Net Income Ratio | -5,968.50% | -1,142.68% | -284.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| EPS Diluted | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| Weighted Avg Shares Out | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
| Weighted Avg Shares Out (Dil) | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
Droplette Launches Droplette 2
BOSTON--(BUSINESS WIRE)--Today, Droplette launched the second generation of its award-winning skincare device. The innovative, R&D-driven company continues to forge ahead, creating best-in-class products for a more connected and effective at-home beauty system. Nurturing good skincare habits is now smarter, and...
Juniper Networks and ServiceNow Collaborate to Deliver End-to-End Automation for Enterprise Network Service Provisioning & Monitoring
SUNNYVALE, Calif.--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, and ServiceNow, the leading digital workflow company making the world work better for everyone, today announced a partnership to deliver end-to-end automation for Managed Service Providers and Enterprises....
Juniper Networks Extends AIOps Leadership with Large Language Model (LLM) Capabilities, Zoom Integration and Expanded Wi-Fi 6E Portfolio
SUNNYVALE, Calif.--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced several new enhancements that make it even easier to deliver predictable, reliable and measurable user experiences from client to cloud. By integrating ChatGPT with Marvis, the...
Juniper Networks® Introduces First Cloud-Native Access Assurance Service Driven by Mist AI®
SUNNYVALE, Calif.--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the latest innovation to its award-winning AI-driven enterprise portfolio, the Juniper Mist® Access Assurance service. This new service leverages Mist AI and a modern microservices cloud...
NW Natural Holdings Reports First Quarter 2023 Results
PORTLAND, Ore.--(BUSINESS WIRE)--Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) reported financial results and highlights including: Reported net income of $71.7 million ($2.01 per share) for the first three months of 2023, compared to earnings of $56.2 million ($1.80...
Juniper Networks Recognizes Black Box as a 2022 Partner of the Year
MUMBAI, India--(BUSINESS WIRE)--Black Box®, a trusted IT solutions provider, has been recognized as a 2022 Partner of the Year by Juniper Networks, a leader in secure, AI-driven networks. Each year, Juniper Networks recognizes partners for their ability to drive innovative...
MECS Awarded Spent Acid Regeneration Plant at Sinopec Zhenhai
ST. LOUIS--(BUSINESS WIRE)--Sinopec Zhenhai Refining and Chemical Co., Ltd (Sinopec), China’s largest integrated refining-chemical enterprise, has contracted with MECS, Inc. (MECS) and MECS Chemical Plants Equipment (Shanghai) Co., LTD., subsidiaries of Elessent Clean Technologies (Elessent), for the license, design, engineering,...
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
Analysts say these are penny stocks to buy. Do you agree?
Source: https://incomestatements.info
Category: Stock Reports